Roche cancer immunotherapy receives new EU approval
European Pharmaceutical Review
JANUARY 16, 2024
Compared with standard intravenous (IV) delivery, Roche stated that its monoclonal antibody biologic shortens treatment time by approximately 80 percent. The European Commission (EC) has approved the EU’s first PD-(L)1 cancer immunotherapy for subcutaneous injection.
Let's personalize your content